A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
Status:
Recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of
obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy
(pMN).